3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
4
Thoracic
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Endocrine
1
CNS
1
Breast
1
Conditions
Neuroendocrine Tumors
34
Pheochromocytoma
14
Thyroid Neoplasms
11
Pituitary Neoplasms
11
Carcinoma, Neuroendocrine
10
Adrenocortical Carcinoma
10
Thyroid Cancer, Papillary
9
Paraganglioma
8
Sarcoma
7
Adrenal Gland Neoplasms
7
Small Cell Lung Carcinoma
6
Neuroblastoma
6
Cushing Syndrome
6
Parathyroid Neoplasms
5
Neoplasms
5
Carcinoma, Medullary
5
Carcinoid Tumor
5
Pancreatic Neoplasms
4
Ovarian Neoplasms
4
Osteosarcoma
4
Multiple Endocrine Neoplasia Type 1
4
Meningioma
4
Insulinoma
4
Cholangiocarcinoma
4
Carcinoma, Renal Cell
4
Carcinoma, Non-Small-Cell Lung
4
Carcinoma, Hepatocellular
4
Adenoma, Islet Cell
4
Adenocarcinoma, Follicular
4
Thyroid Carcinoma, Anaplastic
3
Interventions
belzutifan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
von Hippel-Lindau Disease
×
Endocrine
×
30 days
×
Clear all
NCT04924075
2026-05-28
MK-6482-015
Merck Sharp & Dohme LLC
Phase 2
Recruiting
322 enrolled
1 FDA